A New Implant for Ovarian Cancer Could Change How Doctors Deliver Therapy
Researchers at the University of Galway have developed a flexible implant designed to deliver next-generation therapies for ovarian cancer directly to the tumour site — without the need for repeated surgical procedures. The ovarian cancer implant therapy device, built from a porous biomaterial, has demonstrated the ability to remain fully functional for up to 70 days with zero implant-related complications in preclinical studies, marking a significant step forward in how localised cancer treatment is conceived and administered.
The project, led by Cúram — the Research Ireland Centre for Medical Devices based at the University of Galway — was carried out in collaboration with the University of Minnesota, the Massachusetts Institute of Technology (MIT), and the Wyss Institute. The research has been published in the scientific journal Device, drawing attention from both the oncology and biomedical engineering communities for its novel approach to a long-standing clinical challenge.
Why Ovarian Cancer Has Long Resisted Effective Targeted Treatment
Ovarian cancer is among the most challenging gynaecological cancers to treat effectively, largely because it is frequently diagnosed at a late stage when the disease has already spread throughout the peritoneal cavity — the space surrounding the abdominal organs in people assigned female at birth. According to data from the World Health Organization, ovarian cancer accounts for a disproportionately high share of cancer-related deaths among gynaecological malignancies, precisely because early detection remains elusive and current treatment protocols are blunt instruments relative to the complexity of the disease.
Standard treatment typically involves debulking surgery — the physical removal of as much tumour mass as possible — followed by systemic chemotherapy. While effective in the short term, this approach often fails to prevent recurrence, and patients have limited access to tools that can detect whether the cancer has returned or monitor whether a given therapy is working. As the research team at Galway notes, truly targeted delivery of therapy to the tumour site has been known to outperform systemic administration, but the clinical tools to achieve it reliably have simply not existed — until now.
How the Flexible Biomaterial Implant Delivers Therapy and Monitors Response
The implant itself is constructed from a flexible, porous biomaterial engineered to conform to the internal contours of the human body. Placed inside the peritoneal cavity, the device allows therapeutic agents — including living cell therapies such as immunotherapies — to diffuse directly into the tissue surrounding the tumour. This localised delivery approach sidesteps many of the toxicity and inefficiency issues associated with systemic chemotherapy, which affects the entire body rather than targeting the tumour specifically.
Crucially, the device is connected to an external port through the skin. This design allows clinicians to add new therapies as frequently as required without performing additional surgery, dramatically reducing the procedural burden on patients. The same external port enables continuous monitoring of how the tumour is responding to treatment — a capability that has not previously been available in this clinical context.
"What excites us most is the two-way nature of this approach. Clinicians could use this to track how the immune cells are performing, whether the tumour is responding, and then adapt treatment accordingly. That kind of real-time intelligence is something we've never had access to before in this setting."
— Dr Eimear Dolan, Associate Professor in Biomedical Engineering, University of GalwayDr Aoibhín Sheedy, a PhD graduate with Cúram and the lead researcher on the project, described the gap in available tools that motivated the work. "One of the most frustrating aspects of treating ovarian cancer is that we know localised delivery of therapy works better, but the tools we've had until now weren't built for the job," she said. "We designed this implant with ovarian cancer patients in mind. We wanted an implant that can deliver living cell therapies repeatedly, reliably, and with real precision to the tumour site."
Dr Eimear Dolan's laboratory at the University of Galway was responsible for developing the delivery system embedded within the implant. As an associate professor in biomedical engineering, Dolan's team has focused on making repeated delivery of cellular and biologic therapies both safer and more clinically practical. The two-way monitoring and delivery architecture is widely regarded as the device's most groundbreaking attribute — translating what has traditionally been a one-directional treatment relationship into an ongoing, adaptive clinical dialogue.
International Collaboration Brings Immunotherapy Expertise Into the Design Process
One reason the Galway implant stands out is the depth of expertise assembled across its contributing institutions. The Wyss Institute at Harvard University is well known for its work on bioinspired engineering and has previously contributed to breakthrough medical device projects published in journals such as Nature Biomedical Engineering. MIT's involvement brings computational and materials science capacity that strengthens the biomaterial design underpinning the device. Meanwhile, the University of Minnesota's contribution focuses on the immunotherapy side of the equation — a rapidly expanding field in oncology where repeated, precise delivery of immune-activating cells is essential to therapeutic success.
Dr Martin Felices, an associate professor in medicine at the University of Minnesota, highlighted why novel delivery infrastructure matters so much for immunotherapy specifically. "The tricky part about working with novel therapies, such as immunotherapies, in the setting of ovarian cancer is that repeated delivery is done with outdated materials that are not designed for this setting," he said. "The delivery system, created by Dr Dolan's laboratory, allows for safer repeated delivery of cellular and biologic therapies in the context of the peritoneal cavity."
Immunotherapy, which harnesses the body's own immune system to identify and attack cancer cells, has seen rapid growth as a treatment modality across multiple cancer types. Research published in The Lancet Oncology has consistently shown that localised immune cell delivery outperforms systemic approaches in peritoneal cancers, but clinical implementation has been hampered by the lack of appropriate device infrastructure. The Galway implant is designed precisely to close that gap.
How This Implant Compares to Conventional Ovarian Cancer Treatment Delivery
| Feature | Conventional Treatment | Galway Biomaterial Implant |
|---|---|---|
| Delivery method | Systemic chemotherapy or surgery | Localised, direct peritoneal delivery |
| Repeated therapy access | Requires additional surgical procedures | Via external port, no surgery needed |
| Real-time monitoring | Not available | Continuous, through external port |
| Compatibility with cell therapies | Limited — materials not designed for this | Designed for living cell and biologic therapies |
| Complication rate (preclinical) | Variable | Zero implant-related complications over 70 days |
| Recurrence detection | Limited tools available | Monitoring capability integrated into device |
The comparison underscores just how significant the leap represented by this device may be. Where conventional approaches require clinicians to make treatment decisions with limited real-time data and impose significant procedural burdens on already vulnerable patients, the new implant offers a system that is adaptive, minimally invasive in its ongoing use, and designed around the biological reality of how therapies interact with peritoneal tissue.
Ireland's Broader Cancer Research Investment and What It Signals for Medical Innovation
The Galway implant project does not exist in isolation. Ireland has been investing significantly in medical research infrastructure, with €28 million set aside to fund the second phase of Ireland's largest cancer research programme, involving top universities, charitable organisations, and industrial partners. That funding ecosystem has enabled a string of recent advances, including the identification of specific enzymes linked to better treatment outcomes and the development of compounds capable of damaging cancer cell DNA.
For technology and innovation professionals tracking the intersection of engineering and healthcare, the institutional model behind this project is as instructive as the device itself. Cúram operates as a hub linking academic expertise with clinical application, a model that mirrors how leading technology research centres — from IMEC in Belgium to the Fraunhofer Institutes in Germany — leverage cross-institutional collaboration to accelerate applied research. The University of Galway's position as a node in a transatlantic research network spanning MIT and Harvard's Wyss Institute reflects Ireland's growing role as a serious player in deep tech and biomedical engineering, not just software and fintech.
For professionals in IT, policy, and digital infrastructure who track how public investment shapes innovation ecosystems, the structure of this project offers a useful case study. The combination of public research funding, cross-border academic collaboration, and publication in peer-reviewed journals — in this case Device — represents a model increasingly cited in European Commission discussions around building sovereign research capacity, as outlined in frameworks like the European Research Area policy agenda. More information on Ireland's national cancer research investment can be found via the Health Research Board.
Originally reported by Silicon Republic. Summarised and curated by European Purpose.
